Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.85 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942466 | 0.92 | BRAF (0.85) | BRAFCYP2C9KDRMAPK14KIT | |
| SCHEMBL3929867 | 0.92 | BRAF (1.00) | BRAFCYP2C9KDRMAPK14KIT | |
| SCHEMBL3941819 | 0.91 | BRAF (0.83) | BRAFCYP2C9KDRMAPK14KIT | |
| SCHEMBL3934396 | 0.89 | BRAF (1.00) | BRAFCYP2C9KDRMAPK14LCK | |
| SCHEMBL3944033 | 0.89 | BRAF (0.81) | BRAFCYP2C9KDRMAPK14KIT | |
| SCHEMBL4169598 | 0.88 | BRAF (0.79) | BRAFCYP2C9BTK | |
| SCHEMBL3944141 | 0.87 | BRAF (0.82) | BRAFCYP2C9KDRMAPK14LCK | |
| SCHEMBL3941588 | 0.87 | BRAF (0.82) | BRAFCYP2C9KDRMAPK14LCK | |
| SCHEMBL3932579 | 0.87 | BRAF (1.00) | BRAFCYP2C9KDRMAPK14KIT | |
| SCHEMBL3932791 | 0.87 | BRAF (1.00) | BRAFCYP2C9KDRMAPK14LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | claimed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |